Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Lo WL, Huseby ES. The partitioning of TCR repertoires by thymic selection. J Exp Med. 2024 Oct 07; 221(10).
-
Shi Y, Strasser A, Green DR, Latz E, Mantovani A, Melino G. Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies. Cell Mol Immunol. 2024 Jul; 21(7):790-797.
-
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD, Kumar S, Martin T. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 Aug; 25(8):e374-e387.
-
Racine JJ, Misherghi A, Dwyer JR, Maser R, Forte E, Bedard O, Sattler S, Pugliese A, Landry L, Elso C, Nakayama M, Mannering S, Rosenthal N, Serreze DV. HLA-DQ8 Supports Development of Insulitis Mediated by Insulin-Reactive Human TCR-Transgenic T Cells in Nonobese Diabetic Mice. J Immunol. 2023 Dec 15; 211(12):1792-1805.
-
Ye C, Clements SA, Gu W, Geurts AM, Mathews CE, Serreze DV, Chen YG, Driver JP. Deletion of V?3+CD4+ T cells by endogenous mouse mammary tumor virus 3 prevents type 1 diabetes induction by autoreactive CD8+ T cells. Proc Natl Acad Sci U S A. 2023 Dec 05; 120(49):e2312039120.
-
Andersen M, Bindal P, Michaels P, Elavalakanar P, Liegel J, Dias A, Arnason J, Patell R. Clonal myeloid disorders following CAR T-cell therapy. Ann Hematol. 2023 12; 102(12):3643-3645.
-
Gao J, Dahiya S, Patel SA. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. Br J Haematol. 2023 10; 203(2):161-168.
-
Jones MC, Castonguay C, Nanaware PP, Weaver GC, Stadinski B, Kugler-Umana OA, Huseby ES, Stern LJ, McKinstry KK, Strutt TM, Devarajan P, Swain SL. CD4 Effector TCR Avidity for Peptide on APC Determines the Level of Memory Generated. J Immunol. 2023 06 15; 210(12):1950-1961.
-
Nath K, Mailankody S, Usmani SZ. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies. Hematol Oncol Clin North Am. 2023 12; 37(6):1201-1214.
-
Schmidt J, Chiffelle J, Perez MAS, Magnin M, Bobisse S, Arnaud M, Genolet R, Cesbron J, Barras D, Navarro Rodrigo B, Benedetti F, Michel A, Queiroz L, Baumgaertner P, Guillaume P, Hebeisen M, Michielin O, Nguyen-Ngoc T, Huber F, Irving M, Tissot-Renaud S, Stevenson BJ, Rusakiewicz S, Dangaj Laniti D, Bassani-Sternberg M, Rufer N, Gfeller D, Kandalaft LE, Speiser DE, Zoete V, Coukos G, Harari A. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat Commun. 2023 06 06; 14(1):3188.